万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>心脏和心血管系统
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>外周血管病

Atherosclerosis《动脉粥样硬化》 (官网投稿)

简介
  • 期刊简称ATHEROSCLEROSIS
  • 参考译名《动脉粥样硬化》
  • 核心类别 SCIE(2023版), 外文期刊,
  • IF影响因子
  • 自引率4.50%
  • 主要研究方向医学-PERIPHERAL VASCULAR DISEASE 外周血管病;CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统

主要研究方向:

等待设置主要研究方向
医学-PERIPHERAL VASCULAR DISEASE 外周血管病;CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统

Atherosclerosis《动脉粥样硬化》(半月刊). Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk ...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://www.journals.elsevier.com/atherosclerosis

3、投稿网址:https://www.editorialmanager.com/ATH

4、官网邮箱:arnold.voneckardstein@usz.ch

5、期刊刊期:半月刊,一年出版24期。

202178日星期四

                                 

 

投稿须知【官网信息】

 

Guide for Authors

Atherosclerosis is a fully electronic journal, all manuscripts are to be submitted via the internet. To submit your paper online, click on the link https://www.editorialmanager.com/ath/default.aspx.

Types of paper

Types of papers that can be submitted for consideration by the Editorial Board include:

Original Research Papers are divided into three categories:

Basic Research Papers reporting results of original research or investigation using in vitro cell culture or animal models.

Clinical and Population Research Papers reporting results of investigation in human subjects including observational, interventional and genetic studies. Meta-analyses and genetic association studies will also be published under this category. For publication of clinical trials, genetic association studies and meta-analyses, please consult the dedicated Special Guidelines below.

Translational Research Papers reporting results of research from both bench-to-bedside and bedside-to-bench.

The following word limits apply: abstract 250 words, main text 4000 words (including legends to figures and tables), 5 figures and/or tables in total (authors are encouraged to include additional figures and tables as Supplementary Material) and a maximum of 50 references. Flexibility on word count may be offered after discussion with the Editor.

Methodology papers. They describe novel methods or innovative modifications and applications of existing methods for epidemiological, clinical or experimental research on atherosclerosis or vascular biology. The following word limits apply: abstract 150 words, main text 3000 words (including legends to figures and tables), 3 figures/tables in total and a maximum of 25 references.

Rapid Communications. Atherosclerosis welcomes submissions of manuscripts previously rejected by high-quality journals because of priority reasons as Rapid Communications. Please submit your manuscript together with a cover letter, the reviewers' comments and your rebuttal indicating any revisions made to the manuscript via the journal submission system (https://www.editorialmanager.com/ath) by choosing Rapid Communication as the article type. Your manuscript will be assessed by the Editor in Chief and Co-Editors, who will decide within one week whether the paper is accepted or not, with or without any revision.

Review Articles. Atherosclerosis publishes review articles on topics of great interest or controversy in basic, translational, clinical or population research. Authors who have not been priorly invited to submit a Review by the Editors of Atherosclerosis are advised to write a letter of interest to the Editorial Office, accompanied by an abstract. Based on this, the Editors will encourage or discourage submission. Please note that we only consider Reviews from authors who contributed significant original research to the reviewed research field; a list of previously published works should be provided in the cover letter. In all cases, Review Articles undergo peer review. The following word limits apply: abstract 250 words, main text 5000 words, 6 figures and/or tables in total, and a maximum of 100 references. Authors are encouraged to include a "mechanism/overview" figure and one or more bullet point boxes highlighting the main key-points.

Clinical and Scientific Debates on Atherosclerosis. In this review, two antipodal experts are invited to debate their opposing views on a relevant topic, where every argument is discussed by the author in favour and the author against. Debates articles will consist of an abstract (250 words), a pro section (2500 words) and a con section (2500 words). A total of 6 figures/tables is accepted. References should not exceed a maximum of 100.

Conference reports. Conference reports are accepted for publication in our Journal and should be structured as follows: 1) authors and contact details (postal address of all authors and email address of corresponding author); 2) name of the conference and name of the organizing national atherosclerosis society); 3) conference dates and venue, and website address if available; 4) name(s) of conference President(s); 5) topics covered by the conference as bullet points; 6) conference highlights (prosa or bullet points); 7) conflict of interest statement with respect to the congress (e.g. sponsorship). 1 one-column width figure is allowed. The word count of the entire report (items 1 through 6) shall not exceed 450 words.

Editorials and Correspondence. Editorials will be commissioned by the Editors, who will approach a suitably qualified author to write a commentary on a recently accepted Original Research Paper of particular interest. Editorials should not exceed 1500 words and 20 references. 1 figure or table is allowed.

If you have specific issues that you wish to raise concerning work published in Atherosclerosis, please submit your opinions as a Correspondence. Correspondence articles should not exceed 1000 words (including references), 10 references and 2 figures and/or tables. The inclusion of novel data will increase the chance of acceptance. The Author(s) of the commented manuscript will have the opportunity to respond to the comments in the same issue of the Journal. Please submit Correspondence to the Editor-in-Chief Arnold von Eckardstein.

In each issue, the following manuscripts will be made available free of charges online:

Up to 2 articles selected by the Editor-in-Chief

Invited reviews

Editorials

Contact information

Editor-in-Chief

Professor Arnold von Eckardstein

Institute of Clinical Chemistry

University Hospital and University of Zurich

Rämistrasse 100, Zurich

CH-8091

Switzerland

Fax: +41442554590

E-mail: arnold.voneckardstein@usz.ch

Submission declaration

Submission of an article to Atherosclerosis implies that the work described has not been published previously, except in the form of an abstract or as part of a published lecture or academic thesis.

Submission of an article therefore means:

The article is not under consideration for publication elsewhere.

Publication of the article is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.

If the article is accepted, it will not be published elsewhere by the authors, including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Atherosclerosis will not tolerate plagiarism in any form in submitted manuscripts. Passages of text, data or figures quoted or closely paraphrased from other authors (or from any part of the author's own published work) must be identified as quotations or paraphrases and the sources of such material must be acknowledged. The use of unacknowledged material will be construed as plagiarism. If any manuscript is found to contain plagiarised material the review process will be halted immediately, and the University or Institute of the corresponding Author will be informed.

Atherosclerosis will not tolerate manipulation or enhancement of data. Authors will be asked to provide further evidence for the validity of data, and the University or Institute of the corresponding Author will be informed if such evidence is not forthcoming.

Ethics in publishing

Please see our information on Ethics in publishing.

Atherosclerosis will not tolerate plagiarism in any form in submitted manuscripts. Text copied from copyrighted works from third parties or from the author's own published work, in any section of the manuscript, is unacceptable. Each submission to Atherosclerosis undergoes a check for plagiarism. Manuscripts with excessive overlap with previously published articles are rejected without peer review. To avoid the overlap between your manuscript and previously published works, please cite the relevant articles as references.

Declaration of competing interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using this template and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose the first option in the template. More information.

Studies involving humans

Manuscripts reporting data from research conducted on humans must include a statement of assurance in the Materials and methods section of the manuscript reading that: (1) written informed consent was obtained from each patient included in the study, (2) the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and (3) the study protocol has been priorly approved by the Institution's ethics committee on research on humans.

Identifying information shall not be included in any part of the paper, unless it is essential for scientific purposes and written informed consent for publication in print and electronic version has been obtained. If such consent has not been obtained, personal details of patients included in any part of the paper and in any Supplementary Material must be removed from the submission.

If identifying characteristics are altered to protect anonymity, authors should provide assurance that alterations do not distort scientific meaning and editors should note so. For publication of clinical trials, please consult the dedicated Special Guidelines below.

Studies involving animals

All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. A statement identifying the committee approving the experiments and confirming that all experiments conform to the relevant regulatory standards must be included in the Materials and methods section of the submission. We suggest that researchers carrying out experiments with animals refer to the ARRIVE guidelines and recommendations developed by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) to improve experimental design and reporting of animal research.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

Elsevier supports responsible sharing

Find out how you can share your research published in Elsevier journals.

Open access

Please visit our Open Access page for more information.

Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final.

REVISED SUBMISSIONS

Please ensure the Atherosclerosis style is followed for all revised papers and the checklist uploaded with the revised manuscript Atherosclerosis Checklist

Essential title page information

Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstracts

A structured Abstract must be provided to include the following four sections: Background and aims, Methods, Results; Conclusions (a maximum of 250 words for regular original research papers).

Main Text

The manuscript main text must be structured to include the following sections in this order (please do not deviate from the headers provided):

Introduction

Materials and methods (or Patients and methods)

Results

Discussion

Conflict of interest (mandatory)

Financial support (if applicable)

Author contributions (mandatory)

Acknowledgements (if applicable)

References

Keywords

A keyword summary must be provided; normally 3-7 items should be included.

Abbreviations

Abbreviations should be defined when first used in the text. Use of abbreviations should be kept at a minimum.

Tables

Tables must be submitted as Word files. Tables with titles and legends must be on separate pages with double spacing; they may be included in the same file as the manuscript text or in separate file(s). Authors must list on the title page or in the covering e-mail, the number of figures and/or tables to be found in the paper.

Footnotes to tables

Footnotes to tables must be listed with superscript lowercase letters, beginning with "a."

Footnotes must not be listed with numbers or symbols.

Figure and table legends

Each figure and table legend should have a brief overarching title (with figure number) that describes the entire figure without citing specific panels, followed by a description of each panel, and all symbols used.

If a figure or table contains multiple panels, the letter describing each panel should be capitalized and surrounded by parenthesis: i.e. (A)(B)(C)(D).

References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. For authors' name, the general rule is up to 5 names before et al. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements

Units: Units must be expressed following the international system of units (SI). If other units are mentioned, conversion factors into SI units must be provided.

DNA and protein sequences: Gene names should be italicized; protein products of the loci are not italicized.

For murine models, the gene and protein names are lowercase except for the first letter(e.g. gene: Abcb4; protein: Abcb4).

For humans, the whole gene name is capitalized(e.g. gene: ABCB4; protein ABCB4).

Only gene names approved by the HUGO Gene Nomenclature Committee should be used: www.genenames.org.

Mouse strains and cell lines: Knock-out or transgenic mouse strains and cell lines are italicized and the symbol superscripted (e.g. ob/ob , p53+/+, p53-/-).

p values: p values must be consistently formatted according to the below style throughout the manuscript (including figures and tables):

p<X

p>X

p=X

All p are italicized and lower case.

Language usage and editing service

Language usage and editing service: American or British English should be used, but not a mixture of them.

Words must be written consistently in the same way throughout the manuscript (e.g. non-significant or nonsignificant; down-regulation or downregulation). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop: https://webshop.elsevier.com/language-editing-services/language-editing/ or visit our customer support site https://service.elsevier.com for more information

Supplementary data

Elsevier accepts electronic supplementary material (e-components) to support and enhance presentation of your scientific research. Supplementary files offer the Author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at https://www.elsevier.com/artworkinstructions.Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Graphical abstract

The graphical abstract is mandatory at submission of the revised version of the paper. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: Illustration Service.

……

更多详情:

https://www.elsevier.com/journals/atherosclerosis/0021-9150/guide-for-authors


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭